Merck Unveils Groundbreaking ESCC Trial Results: Unlocking New Hope for Patients
Merck has announced the termination of the KeyVibe-008 Phase 3 trial evaluating the combination of vibostolimab and pembrolizumab in...
Merck has announced the termination of the KeyVibe-008 Phase 3 trial evaluating the combination of vibostolimab and pembrolizumab in...
Neurogene Inc. has made significant progress in its clinical-stage development of NGN-401 gene therapy for Rett syndrome. The therapy...
Merck (MSD outside the US and Canada) has acquired CN201, a novel bispecific antibody, from Curon Biopharmaceutical. CN201 targets...
In a groundbreaking partnership, Unilabs and C2N Diagnostics are collaborating to enhance brain health diagnostics and research in Europe...
Tennessee Cancer Specialists (TCS), the largest community-based oncology practice in eastern Tennessee and the third largest statewide, has joined...
Neurogene’s NGN-401, a gene therapy, has obtained Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating Rett...
eClinical Solutions has introduced enhancements and AI-powered functionalities to its Elluminate Clinical Data Cloud platform. These updates aim to...
Sangamo Therapeutics and Genentech, a Roche Group member, have joined forces to develop intravenous genomic treatments for neurodegenerative diseases....
Artera has improved its ArteraAI Prostate Test to support clinicians in determining the suitability of active surveillance for prostate...
Concentric Analgesics, a biotechnology company, announced the presentation of clinical data for their drug vocacapsaicin at the International Association...